Home › Funds › VIKING GLOBAL INVESTORS LP › BBIO

VIKING GLOBAL INVESTORS LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

VIKING GLOBAL INVESTORS LP reported holding 9,949,219 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$741.0M, representing 2.11% of its reported portfolio and ranking #15 among its reported holdings. VIKING GLOBAL INVESTORS LP has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)9.95M sh
Reported value held$741.02M
Portfolio Weight2.11%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How VIKING GLOBAL INVESTORS LP's BBIO position evolved

VIKING GLOBAL INVESTORS LP first disclosed a stake in BBIO in Q3 2023 at 25,120,991 shares (US$662.4M). The position peaked in Q4 2025 at 14,393,934 shares, worth US$1.10B. Across 12 filings, VIKING GLOBAL INVESTORS LP increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 9,949,219 shares valued at US$741.0M — a reduction of -1,893,215 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 25.12M $662.44M New
Q4 2023 25.12M $1.01B Hold
Q1 2024 25.12M $776.74M Hold
Q2 2024 25.12M $636.31M Hold
Q3 2024 25.12M $639.58M Hold
Q4 2024 25.12M $689.32M Hold
Q1 2025 22.06M $762.45M Reduce
Q2 2025 18.56M $801.22M Reduce
Q3 2025 15.98M $829.89M Reduce
Q4 2025 14.39M $1.10B Reduce
Q1 2026 11.84M $879.42M Reduce
Q2 2026 9.95M $741.02M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has VIKING GLOBAL INVESTORS LP held BBIO?

VIKING GLOBAL INVESTORS LP has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is VIKING GLOBAL INVESTORS LP's current position in BBIO?

As of Q2 2026, VIKING GLOBAL INVESTORS LP holds 9.95M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $741.02M, representing 2.11% of its reported portfolio and ranking #15.

Has VIKING GLOBAL INVESTORS LP been buying or selling BBIO?

In the latest 13F filing (Q2 2026), VIKING GLOBAL INVESTORS LP reduced its position in BBIO. The position peaked in Q4 2025 at 14.39M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.